Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients

References

• FerlayJSoerjomataramIDikshitRCancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012Int J Cancer20151365E359E38625220842
   PubMed Web of Science ®Google Scholar
• FerlayJSoerjomataramIErvikMGLOBOCAN 2012 v1.0Cancer incidence and mortality worldwide: IARC cancer base 11 [webpage on the Internet]Lyon, FranceInternational Agency for Research on Cancer2013 Available from: http://globocan.iarc.frAccessed March 17, 2017
   Google Scholar
• BinefaGRodríguez-MorantaFTeuleAMedina-HayasMColorectal cancer: from prevention to personalized medicineWorld J Gastroenterol201420226786680824944469
   PubMed Web of Science ®Google Scholar
• TwelvesCWongANowackiMPCapecitabine as adjuvant treatment for stage III colon cancerN Engl J Med2005352262696270415987918
   PubMed Web of Science ®Google Scholar
• Van CutsemEHoffPMHarperPOral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trialsBr J Cancer20049061190119715026800
   PubMed Web of Science ®Google Scholar
• CassidyJDouillardJYTwelvesCPharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trialBr J Cancer20069481122112916622438
   PubMed Web of Science ®Google Scholar
• EggingtonSTappendenPPandorACost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancerBr J Cancer20069591195120117031407
   PubMed Web of Science ®Google Scholar
• JohnstonPGStage II colorectal cancer: to treat or not to treatOncologist200510533233415851791
   PubMed Web of Science ®Google Scholar
• BolandCRThibodeauSNHamiltonSRA National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancerCancer Res19985822524852579823339
   PubMed Web of Science ®Google Scholar
• LaihoPLaunonenVLahermoPLow-level microsatellite instability in most colorectal carcinomasCancer Res20026241166117011861399
   PubMed Web of Science ®Google Scholar
• SamowitzWSCurtinKMaKNMicrosatellite instability in sporadic colon cancer is associated with an improved prognosis at the population levelCancer Epidemiol Biomarkers Prev200110991792311535541
   PubMed Web of Science ®Google Scholar
• WrightCMDentOFBarkerMPrognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancerBr J Surg20008791197120210971428
   PubMed Web of Science ®Google Scholar
• KhanSAMorrisMIdreesKColorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patientsJ Pediatr Surg201651111812181727558481
   PubMed Web of Science ®Google Scholar
• KimCGAhnJBJungMEffects of microsatellite instability on recurrence patterns and outcomes in colorectal cancersBr J Cancer20161151253327228287
   PubMed Web of Science ®Google Scholar
• PopatSHubnerRHoulstonRSSystematic review of microsatellite instability and colorectal cancer prognosisJ Clin Oncol200523360961815659508
   PubMed Web of Science ®Google Scholar
• NCC NetworkNCCN clinical practice guidelines in oncology: colon cancer (version 2)2016 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed January 15, 2017
   Google Scholar
• BenattiPGafàRBaranaDMicrosatellite instability and colorectal cancer prognosisClin Cancer Res200511238332834016322293
   PubMed Web of Science ®Google Scholar
• JoverRZapaterPCastellsAThe efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair statusEur J Cancer200945336537318722765
   PubMed Web of Science ®Google Scholar
• GuastadisegniCColafranceschiMOttiniLDogliottiEMicrosatellite instability as a marker of prognosis and response to therapy: a meta-analysis of colorectal cancer survival dataEur J Cancer201046152788279820627535
   PubMed Web of Science ®Google Scholar
• RibicCMSargentDJMooreMJTumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancerN Engl J Med2003349324725712867608
   PubMed Web of Science ®Google Scholar
• SargentDJMarsoniSMongesGDefective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancerJ Clin Oncol201028203219322620498393
   PubMed Web of Science ®Google Scholar
• LambertiCLundinSBogdanowMMicrosatellite instability did not predict individual survival of unselected patients with colorectal cancerInt J Colorectal Dis200722214515216724208
   PubMed Web of Science ®Google Scholar
• KimGPColangeloLHWieandHSPrognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative StudyJ Clin Oncol200725776777217228023
   PubMed Web of Science ®Google Scholar
• Des GuetzGUzzanBNicolasPSchischmanoffOPerretGYMorereJFMicrosatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysisAnticancer Res20092951615162019443375
   PubMed Web of Science ®Google Scholar
• WebberEMKauffmanTLO’ConnorEGoddardKASystematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapyBMC Cancer20151515625884995
   PubMed Web of Science ®Google Scholar
• HemminkiAMecklinJPJärvinenHAaltonenLAJoensuuHMicrosatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapyGastroenterology2000119492192811040179
   PubMed Web of Science ®Google Scholar
• ElsalehHJosephDGrieuFZepsNSpryNIacopettaBAssociation of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancerLancet200035592171745175010832824
   PubMed Web of Science ®Google Scholar
• HutchinsGSouthwardKHandleyKValue of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancerJ Clin Oncol201129101261127021383284
   PubMed Web of Science ®Google Scholar
• KlingbielDSaridakiZRothADBosmanFTDelorenziMTejparSPrognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trialAnn Oncol201526112613225361982
   PubMed Web of Science ®Google Scholar
• TejparSSaridakiZDelorenziMBosmanFRothADMicrosat-ellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzleJ Natl Cancer Inst20111031184184421597023
   PubMedGoogle Scholar
• SinicropeFAFosterNRThibodeauSNDNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapyJ Natl Cancer Inst20111031186387521597022
   PubMedGoogle Scholar
• Des GuetzGSchischmanoffONicolasPPerretGYMorereJFUzzanBDoes microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysisEur J Cancer200945101890189619427194
   PubMed Web of Science ®Google Scholar
• ParkDYSakamotoHKirleySDThe Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancerAm J Pathol200717151509151917982127
   PubMed Web of Science ®Google Scholar
• AlazzouziHAlhopuroPSalovaaraRSMAD4 as a prognostic marker in colorectal cancerClin Cancer Res20051172606261115814640
   PubMed Web of Science ®Google Scholar
• WatanabeTWuTTCatalanoPJMolecular predictors of survival after adjuvant chemotherapy for colon cancerN Engl J Med2001344161196120611309634
   PubMed Web of Science ®Google Scholar
• JenJKimHPiantadosiSAllelic loss of chromosome 18q and prognosis in colorectal cancerN Engl J Med199433142132218015568
   PubMed Web of Science ®Google Scholar
• OgunbiyiOAGoodfellowPJHerfarthKConfirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicatorJ Clin Oncol19981624274339469325
   PubMed Web of Science ®Google Scholar
• JernvallPMäkinenMJKarttunenTJMäkeläJVihkoPLoss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancersBr J Cancer1999795–690390810070888
   PubMed Web of Science ®Google Scholar
• SarliLBottarelliLBaderGAssociation between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18qDis Colon Rectum20044791467148215486743
   PubMed Web of Science ®Google Scholar
• Martínez-LópezEAbadAFontAAllelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancerGastroenterology19981146118011879609754
   PubMed Web of Science ®Google Scholar
• RothADTejparSDelorenziMPrognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trialJ Clin Oncol201028346647420008640
   PubMed Web of Science ®Google Scholar
• OginoSNoshoKIraharaNPrognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancersJ Clin Oncol200927274591459819704056
   PubMed Web of Science ®Google Scholar
• PopatSZhaoDChenZRelationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patientsAnticancer Res2007271B62763317348452
   PubMed Web of Science ®Google Scholar
• HallingKCFrenchAJMcDonnellSKMicrosatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancersJ Natl Cancer Inst199991151295130310433618
   PubMedGoogle Scholar
• CarethersJMHawnMTGreensonJKHitchcockCLBolandCRPrognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancerGastroenterology19981146118811959609755
   PubMed Web of Science ®Google Scholar
• BertagnolliMMRedstonMComptonCCMicrosatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer – a study of CALGB 9581 and 89803J Clin Oncol201129233153316221747089
   PubMed Web of Science ®Google Scholar
• MouradovDDomingoEGibbsPSurvival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutationsAm J Gastroenterol2013108111785179324042191
   PubMed Web of Science ®Google Scholar
• BarrattPLSeymourMTStenningSPDNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular studyLancet200236093431381139112423985
   PubMed Web of Science ®Google Scholar
• HallerDGTaberneroJMarounJCapecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerJ Clin Oncol201129111465147121383294
   PubMed Web of Science ®Google Scholar
• LongleyDBHarkinDPJohnstonPG5-fluorouracil: mechanisms of action and clinical strategiesNat Rev Cancer20033533033812724731
   PubMed Web of Science ®Google Scholar
• PullarkatSTStoehlmacherJGhaderiVThymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapyPharmacogenomics J200111657011913730
   PubMedGoogle Scholar
• LecomteTFerrazJMZinzindohouéFThymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapyClin Cancer Res200410175880588815355920
   PubMed Web of Science ®Google Scholar
• JakobsenANielsenJNGyldenkerneNLindebergJThymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivityJ Clin Oncol20052371365136915735113
   PubMed Web of Science ®Google Scholar
• EtienneMCFormentoJLChazalMMethylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patientsPharmacogenetics2004141278579215608557
   PubMedGoogle Scholar
• CohenVPanet-RaymondVSabbaghianNMorinIBatistGRozenRMethylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapyClin Cancer Res2003951611161512738713
   PubMed Web of Science ®Google Scholar